Full-length IL-33 Augments Pulmonary Fibrosis in an ST2- and Th2-independent, Non-transcriptomic Fashion
Overview
Cell Biology
Authors
Affiliations
Mature IL-33 (MIL33) acting through its receptor, ST2, is known to regulate fibrosis. The precursor, full-length IL-33 (FLIL33), may function differently from MIL33 and independently of ST2. Here we report that genetic deletion of either IL-33 or ST2 attenuates pulmonary fibrosis in the bleomycin model, as does Cre-induced IL-33 deficiency in response to either acute or chronic bleomycin challenge. However, adenovirus-mediated gene delivery of FLIL33, but not MIL33, to the lungs of either wild-type or ST2-deficient mice potentiates the profibrotic effect of bleomycin without inducing a Th2 phenotype. In cultured mouse lung cells, FLIL33 overexpression induces moderate and distinct transcriptomic changes compared with a robust response induced by MIL33, whereas ST2 deletion abrogates the effects of both IL-33 forms. Thus, FLIL33 may contribute to fibrosis in an ST2-independent, Th2-independent, non-transcriptomic fashion, suggesting that pharmacological targeting of both FLIL33 and MIL33 may prove efficacious in patients with pulmonary fibrosis.
Gu S, Wang R, Zhang W, Wen C, Chen C, Liu S Front Immunol. 2024; 15:1436437.
PMID: 39301028 PMC: 11410612. DOI: 10.3389/fimmu.2024.1436437.
Unveiling the multifaceted antitumor effects of interleukin 33.
Arrizabalaga L, Risson A, Ezcurra-Hualde M, Aranda F, Berraondo P Front Immunol. 2024; 15:1425282.
PMID: 38881897 PMC: 11176530. DOI: 10.3389/fimmu.2024.1425282.
Wang Z, Tang N J Cell Commun Signal. 2023; 17(4):1131-1143.
PMID: 37878185 PMC: 10713911. DOI: 10.1007/s12079-023-00788-1.